KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Assets (2016 - 2025)

Historic Return on Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to 0.13%.

  • Halozyme Therapeutics' Return on Assets fell 800.0% to 0.13% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.13%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.14% for FY2025, which is 1000.0% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Return on Assets stood at 0.13% for Q4 2025, which was down 800.0% from 0.28% recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Return on Assets registered a high of 0.38% during Q1 2022, and its lowest value of 0.1% during Q1 2023.
  • Moreover, its 5-year median value for Return on Assets was 0.2% (2021), whereas its average is 0.21%.
  • As far as peak fluctuations go, Halozyme Therapeutics' Return on Assets skyrocketed by 3600bps in 2021, and later crashed by -2800bps in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Return on Assets (Quarter) stood at 0.35% in 2021, then plummeted by -69bps to 0.11% in 2022, then surged by 42bps to 0.16% in 2023, then skyrocketed by 37bps to 0.21% in 2024, then plummeted by -37bps to 0.13% in 2025.
  • Its Return on Assets stands at 0.13% for Q4 2025, versus 0.28% for Q3 2025 and 0.26% for Q2 2025.